-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA accepts Orexo’s IZIPRY resubmission for review

PUBT·10/29/2026 10:04:02
Listen to the news
FDA accepts Orexo’s IZIPRY resubmission for review
  • FDA accepted Orexo’s resubmitted application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose, for review.
  • The agency set a March 29, 2027, target decision date under a six-month review timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.